Aim: Our aim was to clarify the risk factors for graft loss within the first 90 days of kidney transplantation.
Methods:We performed an IRB-approved, retrospective review of the United Network for Organ Sharing database (2010)(2011)(2012)(2013)(2014)(2015) and our own single center database (2004)(2005)(2006)(2007)(2008)(2009)(2010)(2011)(2012)(2013)(2014)(2015). We analyzed risk factors for early graft loss (EGL). EGL was defined as graft loss due to patient death, graft thrombosis, acute rejection, or primary non-function within 90 days of transplantation.Results: At our center, 30 of 676 recipients experienced EGL (4.4%). The most common cause of EGL at our center was recipient death. Demographic variables associated with EGL included: expanded criteria donor (p<0.001), older donors (p=0.003), donors with higher BMI (p=0.004), and higher KDPI (p=0.001). One-, 3-, and 5-year patient survival was lower in recipients with EGL (all p<0.001). Multivariate analysis suggested expanded criteria donor and donor BMI were predictors of EGL (p<0.001).The rate of EGL among patients in the UNOS database was 3.35%, with patient death being the most common cause. Multivariate analysis of the UNOS database revealed only recipient age was a predictor of EGL due to patient death (p<0.001). There were no predictors of EGL due to thrombosis. Previous kidney transplant and recipient age were predictors of EGL due to acute rejection (p=0.002 and p<0.001).
Conclusions:Overall between our center and UNOS database, patient death was the most common cause of EGL. Single center and UNOS data suggest that EGL occurs more frequently in recipients of sub-optimal allografts. Additionally, older age and previous transplant is associated with increased risk for EGL.
Objectives: Our aim was to assess outcomes in White and African American kidney transplant recipients after induction with alemtuzumab.
Materials and Methods:We performed a retrospective study of 464 patients who received deceased-donor kidney transplants and were induced with alem tuzumab between March 2006 and May 2015. We evaluated ethnic influences on patient and graft survival, delayed graft function, allograft failure, and rejection. Results: There were 337 White (67.3%) and 127 African American (25.3%) patients. We observed no significant differences in 1-, 3-, 5-, and 7-year death-censored graft survival. We also observed no significant differences in 1-, 3-, and 5-year patient survival rates. Having African American ethnicity was not a significant predictor of rejection, graft survival, or patient survival. Conclusions: Our results indicate that recipient ethnicity is not a predictor of rejection, graft survival, or patient survival. White and African American kidney transplant recipients induced with alemtuzumab experienced an equalization of outcomes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.